NCT00591383View on ClinicalTrials.gov

Phase I Study of Indibulin in Combination With Erlotinib in Advanced Solid Tumors

PHASE1UnknownINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions
Advanced Solid Tumors
Interventions
DRUG

indibulin

indibulin, dose escalation, 200 mg - 600 mg. Taken twice every day.

DRUG

erlotinib

erlotinib taken at 150 mg every morning with food.

Trial Locations (1)

Unknown

Houston

Sponsors
All Listed Sponsors
lead

Alaunos Therapeutics

INDUSTRY